Monopar acquires exclusive worldwide license for ALXN-1840 from Alexion; pays $4M cash + equity

Monopar Therapeutics

Monopar gets exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson disease; Phase 3 trial met primary endpoint, but Alexion terminated after Phase 2 results.
Upfront: $4M cash ($1M at signing, $3M in 90 days) and 387,329 shares (9.9% beneficial ownership); anti-dilution up to 705,015 total shares.
Future milestones up to $94M plus tiered royalties (low to mid-double digit) on net sales; mid-double digit sublicensing income share until sales.
Cash was ~$6M as of Sep 30, 2024; near-term expenses <$1M for regulatory package; expects substantial doubt about going concern in upcoming 10-Q.
ALXN-1840 has Orphan Drug Designation in US and EU; Monopar plans to initiate FDA discussions; regulatory path uncertain.

item 1.01 item 2.01 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.